Oncology Business Management

Blase Polite, MD, discusses the ramifications of CMS Acting Administrator Andy Slavitt's remarks and lingering concerns about MACRA.

CMS, through the Center for Medicare & Medicaid Innovation, has launched an initiative called the Oncology Care Model that is designed to maintain clinical outcomes and reduce the total cost of care. The obvious first question is, has it been designed to do so?

The FDA granted daratumumab (Darzalex) a breakthrough therapy designation for use in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone as a treatment for patients with multiple myeloma following at least 1 prior therapy.

Television garners the most advertising dollars from cancer centers, but print and Internet media have seen threefold increases in cancer ads,

Ron Kline, MD, explains that there are bound to be technical difficulties with an ambitious program such as the Oncology Care Model.

The FDA has granted a priority review designation to nivolumab as a treatment for patients with previously treated metastatic or recurrent squamous cell carcinoma of the head and neck.